5-Methyltetrahydrofolate

5-MTHF is the biologically active, reduced form of folate that donates methyl groups via methionine synthase (EC 2.1.1.13) to remethylate homocysteine to methionine, driving S-adenosylmethionine (SAM) synthesis for DNA methylation, neurotransmitter production, and one-carbon metabolism. Unlike synthetic folic acid, it bypasses the rate-limiting MTHFR enzyme conversion step, making it effective in the estimated 40–60% of the population carrying MTHFR C677T or A1298C polymorphisms that impair folic acid bioactivation.

Origin & History

5-MTHF is not derived from a single geographic or botanical source but is the predominant circulating form of folate (vitamin B9) found naturally in leafy green vegetables, legumes, liver, and fermented foods. Industrially, it is synthesized via continuous-flow chemical processes from folic acid, involving sequential hydrogenation and methylenation steps, yielding purities above 99% as the calcium salt (calcium L-5-methyltetrahydrofolate). It also accumulates naturally in fermented green tea kombucha through microbial biosynthesis by strains including Microbacterium species, reaching peak concentrations of approximately 55 µg/mL after 21 days of fermentation.

Historical & Cultural Context

Folate as a nutrient was first isolated from spinach by Lucy Wills and colleagues in the 1930s–1940s while investigating nutritional macrocytic anemia in pregnant women in India, with the active vitamin later identified as folic acid in 1941 by Mitchell and colleagues. The specific biologically active form, 5-methyltetrahydrofolate, was characterized in the 1960s as the predominant circulating folate species in human plasma and cerebrospinal fluid, distinguished from the synthetic folic acid form through advanced chromatographic and isotopic techniques. Unlike many botanical ingredients with centuries of traditional use, 5-MTHF has no historical ethnomedicinal record as an isolated compound; its clinical relevance emerged entirely from 20th-century nutritional biochemistry, particularly with the discovery of the MTHFR gene and its common polymorphisms in the 1990s, which transformed understanding of why synthetic folic acid supplementation is inadequate for a large segment of the population. The global public health context of folic acid fortification programs beginning in the 1990s (USA, Canada, and over 80 countries) laid the groundwork for recognition that 5-MTHF supplementation represents a more physiologically appropriate strategy for populations with impaired folate bioactivation.

Health Benefits

- **MTHFR Polymorphism Bypass**: 5-MTHF enters the folate cycle downstream of the MTHFR enzyme, meaning individuals with C677T or A1298C variants who cannot efficiently convert folic acid still achieve effective tissue folate repletion without the enzymatic bottleneck.
- **Homocysteine Reduction**: As the direct methyl donor for methionine synthase, 5-MTHF lowers elevated plasma homocysteine, a cardiovascular risk factor; supplementation consistently reduces homocysteine by 15–25% in controlled trials when combined with B6 and B12.
- **Neural Tube Defect Prevention**: Adequate periconceptional 5-MTHF status reduces the risk of neural tube defects (NTDs) such as spina bifida and anencephaly by up to 70%, consistent with decades of epidemiological and interventional data underpinning global public health recommendations.
- **DNA Synthesis and Repair Support**: 5-MTHF provides one-carbon units essential for de novo thymidylate and purine synthesis via thymidylate synthase and AICAR transformylase, ensuring genomic integrity during rapid cell division and reducing uracil misincorporation into DNA.
- **SAM-Dependent Methylation and Neurotransmitter Synthesis**: By driving methionine and SAM production, 5-MTHF supports methylation of catecholamines (dopamine, norepinephrine), serotonin precursors, and myelin basic protein, with clinical relevance to mood regulation and depression, particularly in patients with low folate status.
- **Anemia Prevention**: 5-MTHF corrects megaloblastic anemia caused by folate deficiency by restoring thymidylate synthesis and enabling proper red blood cell maturation; unlike folic acid, it does not mask vitamin B12 deficiency-related neurological symptoms in the same way when correctly dosed.
- **Cardiovascular Risk Reduction**: Through homocysteine lowering and maintenance of endothelial nitric oxide synthase (eNOS) coupling, adequate 5-MTHF status is associated with improved endothelial function and reduced markers of oxidative vascular stress in observational and intervention studies.

How It Works

5-MTHF functions as the obligate methyl donor for methionine synthase (EC 2.1.1.13), transferring its N5-methyl group to cobalamin (vitamin B12)-bound cob(I)alamin, which then remethylates homocysteine to methionine; this regenerates tetrahydrofolate (THF) for continued one-carbon cycling and produces methionine for S-adenosylmethionine (SAM) biosynthesis via methionine adenosyltransferase. SAM subsequently serves as the universal methyl donor for over 200 methyltransferase reactions governing DNA CpG methylation (via DNMT1, DNMT3a/b), histone methylation, phosphatidylcholine synthesis, and neurotransmitter N-methylation, fundamentally regulating gene expression and cellular differentiation. Critically, 5-MTHF does not require activation by dihydrofolate reductase (DHFR) or methylenetetrahydrofolate reductase (MTHFR), the enzyme encoded by the polymorphic MTHFR gene; this allows direct cellular utilization regardless of MTHFR enzymatic activity, unlike folic acid which must traverse both reduction steps. Additionally, 5-MTHF maintains eNOS in its coupled, nitric-oxide-producing state by recycling the eNOS cofactor tetrahydrobiopterin (BH4) indirectly through suppression of oxidative stress associated with hyperhomocysteinemia, thereby supporting vascular endothelial function.

Scientific Research

The evidence base for 5-MTHF is substantial for specific endpoints such as neural tube defect prevention and homocysteine reduction, supported by multiple randomized controlled trials and systematic reviews that form the basis of global dietary recommendations, though direct head-to-head comparisons of 5-MTHF versus folic acid in large independent RCTs are less numerous than the broader folate literature. Comparative bioavailability studies confirm that calcium L-5-methyltetrahydrofolate raises red blood cell and plasma folate levels at least as effectively as equimolar folic acid, with advantages in MTHFR-variant carriers documented in smaller controlled trials of 50–200 participants. For depression and neuropsychiatric indications, pilot RCTs and open-label studies of 15 mg/day adjunctive 5-MTHF report significant reductions in depressive symptom scores, though sample sizes remain small (n=20–100) and replication in large multicenter trials is limited. A cohort study examining cerebrospinal fluid 5-MTHF in children with autism spectrum disorder found no significant correlation between CSF 5-MTHF levels and ASD symptom severity, adaptive behavior, or cognitive outcomes (r=0.38, p=0.04), and highlighted high natural variability in pediatric CSF folate, indicating that the clinical utility of CSF 5-MTHF as a biomarker in ASD requires further investigation.

Clinical Summary

The most robustly evidenced clinical application of 5-MTHF is periconceptional supplementation for neural tube defect prevention, where folate intervention trials have demonstrated up to 70% risk reduction, underpinning recommendations of 400–800 µg daily for women of childbearing age. Homocysteine-lowering trials confirm that 5-MTHF at doses of 400–1000 µg/day reduces plasma homocysteine by approximately 15–25% in hyperhomocysteinemic individuals, particularly when co-administered with vitamins B6 and B12, with cardiovascular surrogate endpoint improvements observed but definitive mortality benefits not yet established from 5-MTHF-specific trials. For depression, small RCTs and case series using 5-MTHF at 7.5–15 mg/day as adjunctive therapy to antidepressants report clinically meaningful reductions in Hamilton Depression Rating Scale scores, especially in patients with low baseline folate or MTHFR variants, but large Phase III trials are absent. The ASD CSF study adds context that elevated or supplemented 5-MTHF in cerebrospinal fluid does not correlate linearly with neurodevelopmental clinical markers, reflecting the complexity of folate metabolism in the central nervous system and the need for further controlled trials to define therapeutic windows in neurological indications.

Nutritional Profile

5-MTHF is a micronutrient compound rather than a macronutrient source; it provides no caloric, protein, fat, or carbohydrate content. As a reduced pteroylmonoglutamate, its molecular weight is 459.46 g/mol (calcium salt: 497.5 g/mol), and it is water-soluble with pH-dependent stability (optimal stability at pH 4–7; degrades under alkaline conditions, UV light, and oxidative environments). In dietary sources, leafy greens such as spinach provide 100–200 µg DFE per 100g primarily as polyglutamate folates requiring intestinal hydrolysis, whereas supplemental calcium L-5-MTHF is the monoglutamate form with direct intestinal absorption via the proton-coupled folate transporter (PCFT/SLC46A1) and reduced folate carrier (RFC/SLC19A1). Bioavailability of supplemental 5-MTHF is approximately 85–100% relative to folic acid under standard conditions, and critically is not subject to saturation of DHFR at high intakes (a limitation of folic acid that leads to unmetabolized folic acid in plasma). No associated phytochemicals, cofactors, or secondary metabolites are intrinsic to the isolated compound; synergistic co-factors in metabolism include vitamin B12, vitamin B6, riboflavin (FAD as MTHFR cofactor), and zinc.

Preparation & Dosage

- **Calcium L-5-methyltetrahydrofolate (oral supplement, tablet/capsule)**: 400–800 µg/day for general folate supplementation and neural tube defect prevention; up to 1000 µg/day for MTHFR variant carriers or elevated homocysteine.
- **High-dose 5-MTHF (prescription or clinical formulation)**: 7.5–15 mg/day used adjunctively in treatment-resistant depression protocols under medical supervision; this dose range is approximately 15–37 times the standard RDA equivalent.
- **Fermented food sources (kombucha)**: Green tea kombucha fermented for 7–21 days naturally accumulates 5-MTHF at concentrations of 39–55 µg/mL as measured by HPLC-DAD; not a standardized supplemental source but demonstrates natural bioavailability from fermented matrices.
- **Prenatal supplements**: Typically formulated at 400–1000 µg per serving as calcium L-5-MTHF, replacing or complementing folic acid; ideally initiated at least one month before conception and continued through the first trimester.
- **Industrial synthesis form**: Produced via continuous-flow hydrogenation of folic acid (53.54% yield, 71.4-minute residence time) as calcium salt with >99% purity for pharmaceutical-grade supplementation.
- **Timing**: No strict timing requirement demonstrated; consistent daily intake preferable; may be taken with food to minimize any gastrointestinal sensitivity at higher doses.
- **Standardization**: Pharmaceutical-grade calcium L-5-MTHF is standardized to >99% purity; dietary supplements should declare content as L-methylfolate equivalents in micrograms of dietary folate equivalents (DFE).

Synergy & Pairings

5-MTHF demonstrates its strongest metabolic synergy with vitamin B12 (cobalamin) and vitamin B6 (pyridoxine), as all three are required for complete homocysteine remethylation and transsulfuration pathways; combined supplementation reduces homocysteine more effectively than any single B vitamin alone, and B12 deficiency renders 5-MTHF metabolically inactive by trapping it as the methyl-folate trap. Riboflavin (vitamin B2) functions as the essential FAD cofactor for MTHFR enzyme activity, and its co-supplementation with 5-MTHF is particularly relevant in individuals homozygous for the MTHFR C677T variant, where riboflavin repletion has been shown to independently lower homocysteine and blood pressure in this genotype. Zinc supports methionine synthase activity and SAM-dependent methyltransferases, while magnesium participates in ATP-dependent steps of the methionine cycle, making a comprehensive B-vitamin and mineral formula a rational stack for optimizing one-carbon metabolism.

Safety & Interactions

At standard supplemental doses of 400–1000 µg/day, 5-MTHF is considered safe with a well-established tolerability profile; adverse effects are rare and may include mild gastrointestinal symptoms (nausea, bloating) at higher doses, and isolated reports of sleep disturbances, irritability, or anxiety at doses above 5 mg/day in sensitive individuals, potentially due to rapid increases in methylation flux. A critical drug interaction exists with methotrexate, a DHFR inhibitor and antifolate chemotherapy/immunosuppressant agent; 5-MTHF can reduce methotrexate toxicity but may also attenuate its therapeutic efficacy in oncology settings, and co-administration should only occur under specialist guidance. 5-MTHF may also interact with anticonvulsants including phenytoin, carbamazepine, and valproate, which reduce folate absorption and increase degradation; conversely, high-dose folate may alter serum levels of these drugs and should be monitored. In pregnancy, 5-MTHF at recommended doses (400–800 µg/day) is safe and preferred over folic acid for women with MTHFR variants; doses above 1 mg/day should be medically supervised, and unlike folic acid, 5-MTHF does not mask vitamin B12 deficiency hematological signs at typical supplemental doses, though neurological masking at very high doses remains a theoretical concern requiring further study.